|Nom||Titre||Payer||Exercé||Année de naissance|
|Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA||Founder, CEO & Executive Director||502,1k||S.O.||S.O.|
|Dr. Nicolas G. Loebel Ph.D.||President, CTO & Executive Director||586,6k||S.O.||S.O.|
|Dr. Simon Sinclair Ph.D.||Chief Medical Officer & Director||73,16k||S.O.||1972|
|Mr. Vipul Shah||VP & CFO||57,77k||S.O.||S.O.|
|Angelika Vance||Vice President of Corporate Communications||S.O.||S.O.||S.O.|
|Mr. Matt Ross||Vice President of Sales & Marketing||S.O.||S.O.||S.O.|
|Mr. Nikita Parkhaev||Company Secretary||S.O.||S.O.||S.O.|
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
L’ISS Governance QualityScore de Ondine Biomedical Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..